Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David T. Winn is active.

Publication


Featured researches published by David T. Winn.


Bioorganic & Medicinal Chemistry Letters | 1999

Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one

James P. Edwards; Robert I. Higuchi; David T. Winn; Charlotte L. F. Pooley; Thomas R. Caferro; Lawrence G. Hamann; Lin Zhi; Keith B. Marschke; Mark E. Goldman; Todd K. Jones

A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone.


Bioorganic & Medicinal Chemistry Letters | 1998

Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines.

Lawrence G. Hamann; David T. Winn; Charlotte L. F. Pooley; Christopher M. Tegley; Sarah J. West; Luc J. Farmer; Lin Zhi; James P. Edwards; Keith B. Marschke; Dale E. Mais; Mark E. Goldman; Todd K. Jones

A series of nonsteroidal human progesterone receptor (hPR) antagonists based on conformationally-restricted analogues of a 6-aryl-1,2-dihydro-2,2,4-trimethylquinoline pharmacophore were synthesized and evaluated for their ability to bind to the human progesterone receptor and inhibit progesterone-stimulated reporter gene expression in mammalian cells.


Bioorganic & Medicinal Chemistry Letters | 2009

Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.

Amogh Boloor; Denise Hanway; Maria Joshi; David T. Winn; Gabriel Mendez; Marlena Walls; Ping Wei; Fuxin Qian; Xiaoli Zhang; Yuliang Zhang; Michael Hepperle; Xinqiang Li; David Alan Campbell; Juan Manuel Betancort

A new series of NS3/4A protease boronic acid inhibitors is described. The compounds show good biochemical potency and cellular activity. The peptidomimetic inhibitors were evaluated against proteases from different HCV genotypes and clinically relevant NS3/4A mutants. Compound 28 displayed subnanomolar to single digit nanomolar potencies in the enzymatic assays and an EC50 of 25 nM in the replicon cell-based assay.


Bioorganic & Medicinal Chemistry Letters | 1994

Synthesis of β-cyclodextrin oximes

Mark A. Mortellaro; Sungyeap Hong; David T. Winn; Anthony W. Czarnik

Abstract The primary- and secondary-side oxime derivatives of β-cyclodextrin have been prepared as hydrolysis reagents. The secondary-side derivative has been converted to the first secondary-side keto-cyclodextrin.


Bioorganic & Medicinal Chemistry Letters | 2009

Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.

Juan Manuel Betancort; David T. Winn; Ruzhang Liu; Quansheng Xu; Junjuan Liu; Wensheng Liao; Shuhui Chen; David Carney; Denise Hanway; James Schmeits; Xinqiang Li; Eric M. Gordon; David Alan Campbell

The synthesis and biochemical evaluation of novel cyanothiazolidine inhibitors of dipeptidyl peptidase 4 (DPP4) is described. Their main structural feature is a constrained bicyclic core that prevents the intramolecular formation of inactive cyclic species. The inhibitors show good to moderate biochemical potency against DPP4 and display distinct selectivity profiles towards DPP7, DPP8 and DPP9 depending on their substitution.


Archive | 1995

Steroid receptor modulator compounds and methods

Todd K. Jones; Mark E. Goldman; Charlotte L. F. Pooley; David T. Winn; James P. Edwards; Sarah J. West; Christopher M. Tegley; Lin Zhi; Lawrence G. Hamann; Luc J. Farmer; Robert L. Davis


Archive | 1995

Tricyclic steroid receptor modulator compounds and methods

Todd K. Jones; David T. Winn; Mark E. Goldman; Lawrence G. Hamann; Lin Zhi; Luc J. Farmer; Robert L. Davis


Proceedings of the National Academy of Sciences of the United States of America | 2005

High-resolution functional proteomics by active-site peptide profiling

Eric Okerberg; Jiangyue Wu; Baohong Zhang; Babak Samii; Kelly Blackford; David T. Winn; Kevin Shreder; Jonathan J. Burbaum; Matthew P. Patricelli


Archive | 2004

Heterocyclic boronic acid compounds

David Alan Campbell; David T. Winn; Juan Manuel Betancort


Archive | 2008

Macrocyclic hepatitis c protease inhibitors

David Alan Campbell; Michael Hepperle; David T. Winn; Juan Manuel Betancort

Collaboration


Dive into the David T. Winn's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge